Tumor Necrosis Factor Receptor 2 (TNFR2): An Emerging Target in Cancer Therapy

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Tumor necrosis factor receptor 2 (TNFR2) has been historically underestimated in cancer therapy despite its known roles in inflammation and immunity.
• Recent advances in immunotherapy and the identification of TNFR2's role in regulating T-cells have renewed interest in its therapeutic potential.
• TNFR2's function extends beyond immunosuppression, influencing T-cell co-stimulation, sensitizing cells to cytotoxicity, and acting as an oncogene.

Purpose of the Study:

• To review the multifaceted roles of TNFR2 in tumor biology and cancer immunity.
• To summarize preclinical findings on TNFR2 agonists and antagonists as cancer therapeutics.
• To explore the molecular and cellular mechanisms underlying TNFR2-mediated anti-tumor activities.

Main Methods:

• Review of existing preclinical studies and literature on TNFR2 signaling pathways.
• Analysis of data on the efficacy of TNFR2 agonists and antagonists in various cancer models.
• Discussion of immunoregulatory functions of TNFR2 in the tumor microenvironment.

Main Results:

• TNFR2 exhibits dual roles, promoting immunosuppression via regulatory T-cells (Tregs) but also enhancing anti-tumor immunity through CD8+ T-cell co-stimulation.
• Both TNFR2 agonists and antagonists have demonstrated significant anti-tumor activity in preclinical cancer models.
• TNFR2 signaling influences tumor cell sensitivity to cytotoxic agents and can function as an oncogene.

Conclusions:

• TNFR2 is a critical regulator within the tumor microenvironment with complex, context-dependent functions.
• Targeting TNFR2, using either agonists or antagonists, holds significant promise for novel cancer immunotherapies.
• Further investigation into TNFR2-associated mechanisms is crucial for optimizing therapeutic strategies.